Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Citi raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...

Ukraine and its European allies sought on Sunday to present a united front ahead of a meeting this week between President ...

The July CPI is expected to show a rise in annual retail inflation. AMC and Cisco among those reporting earnings. Nvidia ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...

Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.